Corbus Pharmaceuticals Holdings, Inc. Stock
Stocks
CRBP
US21833P3010
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 6.340 USD | -7.04% |
|
-18.09% | -22.11% |
| 09-14 | Corbus Pharmaceuticals Holdings, Inc. - Special Call | |
| 09-14 | Corbus Pharma Reports Positive Top-Line Data From Weight-Loss Drug Study | DJ |
| Market Cap | 132M 117M 110M 99.97M 188M 12.7B 190M 1.32B 513M 6.48B 495M 484M 20.85B | P/E 2026 * |
-1.16x | P/E 2027 * | -1.1x |
|---|---|---|---|---|---|
| Enterprise Value | 132M 117M 110M 99.97M 188M 12.7B 190M 1.32B 513M 6.48B 495M 484M 20.85B | EV / Sales 2026 * |
119x | EV / Sales 2027 * | 55x |
| Free-Float |
98.76% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CRBP | Delayed | |
CBOE
| CRBP | Real-time | |
|
London S.E.
| 0SZI | Delayed | |
|
Tradegate
| 3371 | Real-time | |
|
Deutsche Boerse AG
| 3371 | Delayed | |
|
Börse Stuttgart
| 3371 | Delayed | |
|
Boerse Muenchen
| 3371 | Real-time |
Last Transcript: Corbus Pharmaceuticals Holdings, Inc.
| 1 day | -7.04% | ||
| 1 week | -18.09% | ||
| Current month | -7.04% | ||
| 1 month | -41.89% | ||
| 3 months | -32.41% | ||
| 6 months | -32.48% | ||
| Current year | -22.11% |
| 1 week | 6.25 |  | 7.59 |
| 1 month | 6.25 | | 11.6 |
| Current year | 6.25 | | 12.88 |
| 1 year | 6.25 | | 20.56 |
| 3 years | 3.03 | | 61.9 |
| 5 years | 2.11 | | 61.9 |
| 10 years | 2.11 | | 323.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 51 | 2014-04-10 |
Sean Moran
DFI | Director of Finance/CFO | 68 | 2014-04-10 |
Leonardo Nicacio
CTO | Chief Tech/Sci/R&D Officer | 48 | 2026-07-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
BRD | Director/Board Member | 51 | 2014-04-10 |
John Jenkins
BRD | Director/Board Member | 68 | 2018-06-04 |
Rachelle Jacques
CHM | Chairman | 54 | 2025-05-14 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/14/26 | Sell | Director | -2,000 | 0.0103% | ||
| 8/16/26 | Free | Chief Technology Officer | 250,009 | 1.3494% | ||
| 8/11/26 | Buy | Executive/Senior Manager | 2,600 | 0.0140% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.04% | -18.09% | -49.88% | -5.93% | 132M | |
| +4.16% | -0.36% | +49.37% | +94.17% | 74.46B | |
| -0.61% | +0.69% | +36.36% | +82.72% | 60.14B | |
| -2.54% | -0.21% | +6.34% | +31.72% | 48.15B | |
| -3.02% | -2.67% | +37.26% | +32.51% | 44.25B | |
| +0.31% | +7.94% | +340.88% | +643.82% | 43.99B | |
| -1.96% | -1.71% | +5.30% | +99.46% | 41.61B | |
| +3.32% | +3.49% | +11.18% | +51.23% | 29.97B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 29.31B | |
| -4.86% | -8.24% | -24.60% | +330.06% | 24.93B | |
| Average | -0.75% | +0.58% | +44.90% | +138.25% | 39.69B | |
| Weighted average by Cap. | +0.17% | +1.83% | +60.03% | +145.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.11M 988K 923K 842K 1.58M 107M 1.6M 11.15M 4.32M 54.55M 4.17M 4.08M 176M | 2.4M 2.13M 1.99M 1.82M 3.41M 231M 3.46M 24.08M 9.33M 118M 9.01M 8.81M 379M |
| Net income | -116M -103M -96.63M -88.12M -165M -11.2B -168M -1.17B -452M -5.71B -437M -427M -18.38B | -135M -120M -112M -102M -192M -13.02B -195M -1.36B -526M -6.63B -507M -496M -21.36B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-01 | US$6.340 | -7.04% | 802,327 |
| 26-09-30 | US$6.820 | +2.87% | 508,287 |
| 26-09-29 | US$6.630 | -4.19% | 786,178 |
| 26-09-28 | US$6.920 | -3.08% | 932,059 |
| 26-09-25 | US$7.140 | -4.16% | 708,577 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRBP Stock
Select your edition
All financial news and data tailored to specific country editions
